An Oral Secretagogue, Not a SARM
MK-677 (Ibutamoren) is frequently mischaracterized in fitness circles as a SARM (Selective Androgen Receptor Modulator). This is pathologically incorrect. MK-677 is an oral, non-peptide growth hormone secretagogue. It binds exclusively to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, completely bypassing androgen receptors.
Unlike peptide secretagogues (such as Ipamorelin or CJC-1295) which require subcutaneous injection, MK-677 is an active spiroindoline sulfonamide that survives first-pass hepatic metabolism. A single oral dose stimulates a prolonged, 24-hour elevation of both Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1).
Clinical Efficacy vs. Metabolic Risk
The clinical data on MK-677 is substantial. In placebo-controlled trials (e.g., Svensson et al., 1998), an oral dose of 25mg/day successfully elevated IGF-1 by 60% and increased fat-free mass over a 12-month period in healthy older adults.
However, this sustained, unnatural 24-hour elevation comes with a severe metabolic penalty: insulin resistance. Because MK-677 mimics ghrelin - the hormone that signals starvation - it aggressively stimulates appetite and elevates fasting blood glucose. Chronic administration frequently pushes users into prediabetic HbA1c ranges if not actively monitored and mitigated.
Dosing Tiers: Diminishing Returns
Clinical consensus in optimization circles strongly cautions against the original 25mg trial doses, favoring a "minimum effective dose" approach to mitigate glycemic disruption:
• 10 mg/day (The Optimization Dose): Provides approximately 80% of the maximum IGF-1 elevation possible with MK-677, while keeping fasting glucose elevation minimal. This is the preferred dose for longevity and sleep architecture enhancement.
• 15 mg/day (The Threshold Dose): The maximum dose recommended before insulin resistance becomes difficult to manage without exogenous intervention (e.g., Berberine, Metformin).
• 25 mg/day (The Clinical Trial Dose): Maximizes IGF-1 but reliably induces severe appetite stimulation, water retention (edema), and fasting glucose elevation. Highly discouraged for long-term use.
Optimal Timing and Administration
Due to its profound somnogenic (sleep-inducing) properties and intense appetite stimulation, MK-677 should be administered once daily, 30-60 minutes before bed. Nocturnal dosing aligns the drug's initial pulse with the body's natural Stage 4 deep sleep cycle and allows the user to sleep through the most aggressive peak of ghrelin-induced hunger.